Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefadroxil
Drug ID BADD_D00379
Description Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
Indications and Usage For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes
Marketing Status Prescription; Discontinued
ATC Code J01DB05
DrugBank ID DB01140
KEGG ID D00257
MeSH ID D002434
PubChem ID 47965
TTD Drug ID D0X9ZC
NDC Product Code 65862-083; 63187-883; 0143-9767; 67296-1038; 57237-098; 16714-388; 45865-503; 16714-389; 63629-7615; 43063-553; 72189-103; 65862-359; 68071-4690; 68788-7484; 0143-9948; 68071-4938; 43063-595; 70934-056; 0143-9947; 57237-097; 67296-1727; 70934-081; 65862-084; 68180-182; 68180-181; 68180-180; 57237-096; 68071-5234; 65862-085; 0143-9766; 53002-2290; 50090-0580; 16714-390; 55289-589; 50090-1915; 0093-3196; 68071-4515; 0093-4059; 66267-045; 70518-2538
Synonyms Cefadroxil | Cephadroxyl | Cefadroxil Anhydrous | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Ultracef | Bidocef | Duricef | BL-S 578 | BL S 578 | BLS 578 | BL-S578 | BL S578 | BLS578 | S-578 | S 578 | S578 | 4-Hydroxycephalexin | 4 Hydroxycephalexin | Cefadroxil Monohydrate
Chemical Information
Molecular Formula C16H17N3O5S
CAS Registry Number 50370-12-2
SMILES CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Angioedema10.01.05.009; 23.04.01.0010.003833%Not Available
Anxiety19.06.02.0020.002555%
Aplastic anaemia01.03.03.002--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Blood bilirubin increased13.03.01.008--
Blood creatinine increased13.13.01.004--
Blood lactate dehydrogenase increased13.04.02.002--
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Chest discomfort02.02.02.009; 08.01.08.019; 22.02.08.0010.002555%Not Available
Cholestasis09.01.01.001--Not Available
Complications of transplanted liver09.01.08.011; 12.02.09.014--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.0020.002555%
Diarrhoea07.02.01.001--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Drug hypersensitivity10.01.01.0010.002555%Not Available
Dyspepsia07.01.02.001--
Dyspnoea02.01.03.002; 22.02.01.0040.002555%
Eosinophilia01.02.04.001--
Erythema23.03.06.0010.002555%Not Available
Erythema multiforme10.01.03.015; 23.03.01.003--
Gastrointestinal disorder07.11.01.001--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages